Single-cell metabolomics in rare disease: From technology to disease.

IF 1.1 Q2 MEDICINE, GENERAL & INTERNAL Intractable & rare diseases research Pub Date : 2024-05-31 DOI:10.5582/irdr.2023.01073
Lisha Li, Yiqin Zhang, Jing Zhou, Jing Wang, Ling Wang
{"title":"Single-cell metabolomics in rare disease: From technology to disease.","authors":"Lisha Li, Yiqin Zhang, Jing Zhou, Jing Wang, Ling Wang","doi":"10.5582/irdr.2023.01073","DOIUrl":null,"url":null,"abstract":"<p><p>With the development of clinical experience and technology, rare diseases (RDs) are gradually coming into the limelight. As they often lead to poor prognosis, it is urgent to promote the accuracy and rapidity of diagnosis and promote the development of therapeutic drugs. In recent years, with the rapid improvement of single-cell sequencing technology, the advantages of multi-omics combined application in diseases have been continuously explored. Single-cell metabolomics represents a powerful tool for advancing our understanding of rare diseases, particularly metabolic RDs, and transforming clinical practice. By unraveling the intricacies of cellular metabolism at a single-cell resolution, this innovative approach holds the potential to revolutionize diagnosis, treatment, and management strategies, ultimately improving outcomes for RDs patients. Continued research and technological advancements in single-cell metabolomics are essential for realizing its full potential in the field of RDs diagnosis and therapeutics. It is expected that single-cell metabolomics can be better applied to RDs research in the future, for the benefit of patients and society.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145402/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intractable & rare diseases research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5582/irdr.2023.01073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

With the development of clinical experience and technology, rare diseases (RDs) are gradually coming into the limelight. As they often lead to poor prognosis, it is urgent to promote the accuracy and rapidity of diagnosis and promote the development of therapeutic drugs. In recent years, with the rapid improvement of single-cell sequencing technology, the advantages of multi-omics combined application in diseases have been continuously explored. Single-cell metabolomics represents a powerful tool for advancing our understanding of rare diseases, particularly metabolic RDs, and transforming clinical practice. By unraveling the intricacies of cellular metabolism at a single-cell resolution, this innovative approach holds the potential to revolutionize diagnosis, treatment, and management strategies, ultimately improving outcomes for RDs patients. Continued research and technological advancements in single-cell metabolomics are essential for realizing its full potential in the field of RDs diagnosis and therapeutics. It is expected that single-cell metabolomics can be better applied to RDs research in the future, for the benefit of patients and society.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
罕见疾病中的单细胞代谢组学:从技术到疾病。
随着临床经验和技术的发展,罕见病(RDs)逐渐成为人们关注的焦点。由于罕见病往往导致预后不良,因此提高诊断的准确性和快速性、促进治疗药物的研发迫在眉睫。近年来,随着单细胞测序技术的快速发展,多组学在疾病中的联合应用优势不断被挖掘出来。单细胞代谢组学是推进我们对罕见病(尤其是代谢性 RD)的认识和改变临床实践的有力工具。通过以单细胞分辨率揭示细胞代谢的复杂性,这种创新方法有望彻底改变诊断、治疗和管理策略,最终改善 RDs 患者的预后。单细胞代谢组学的持续研究和技术进步对于充分发挥其在 RDs 诊断和治疗领域的潜力至关重要。预计未来单细胞代谢组学将更好地应用于 RDs 研究,造福患者和社会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Intractable & rare diseases research
Intractable & rare diseases research MEDICINE, GENERAL & INTERNAL-
CiteScore
2.10
自引率
0.00%
发文量
29
期刊最新文献
A patient treated with ofatumumab for myasthenia gravis in conjunction with systemic lupus erythematosus and thyroid carcinoma. Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China. Epidemiological estimates of paroxysmal nocturnal hemoglobinuria in Bulgaria. Functional impairments in NBIA patients: Preliminary results. Genetic analysis of a novel FBN1 mutation in a pediatric Marfan syndrome patient.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1